Rheumatology
From the Journals
Sacroiliac structural changes show on MRI in nonradiographic axial SpA despite no inflammation
A study lends evidence for justifying earlier treatment with biologics for some patients.
From the Journals
ABP 501 equivalent in efficacy to adalimumab for moderate to severe RA
Treatments for RA continue to evolve with a newly approved adalimumab biosimilar.
From the Journals
Biologics after methotrexate fails: Huge cost, minimal benefit
Prescribing biologics for RA as a first approach is like throwing money in the trash.
From the Journals
Osteoarthritis contributes more to difficulty walking than do diabetes, CVD
The ability of hip and knee OA to predict difficulty walking increased with the number of joints affected and acted additively with either...
Conference Coverage
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
CHICAGO – Can use of biosimilars save money for IBD patients and health care systems?
Conference Coverage
Experts bust common sports medicine myths
SAN DIEGO – Is it okay for pregnant women to attend CrossFit classes? Are patients who run for fun at increased risk for osteoarthritis? Does...
News
FDA approves sarilumab for DMARD-intolerant RA patients
The drug is the first to target the interleukin-6 receptor.
News
FDA approves first specific treatment for giant cell arteritis
The approval of tocilizumab was made with breakthrough therapy and priority review designations.
From the Journals
Intervention improves use of treat to target in RA
A learning collaborative intervention significantly boosted use of the treat-to-target approach to rheumatoid arthritis treatment at rheumatology...
From the Journals
Mepolizumab proves effective for eosinophilic granulomatosis with polyangiitis
The anti–interleukin-5 monoclonal antibody beat placebo for total accrued weeks of remission and remission after 36 and 48 weeks of treatment.
Conference Coverage
Long-term TNFi tapering possible for some with ankylosing spondylitis
BIRMINGHAM, ENGLAND – A proportion of patients with ankylosing spondylitis (AS) were able to remain on a reduced-dose regimen of a tumor necrosis...